Who
Goldman Myla Lai
Director
Company insider
Files Form 4 as: Director, Quanterix; Director, West Pharmaceutical Services; Director, Akoya Biosciences; Director, Sequenom; EVP & Chief Medical Officer, Labcorp Holdings.
In numbers
- Trades disclosed
- 406
- Buys
- 3
- Sells
- 30
- Bought
- $118K
- Sold
- $17.9M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 5 Jan 2006
- Last trade
- 8 Jul 2026
- Last filed
- 9 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 9 Jul 2026 | QTRX QuanterixLife-science tools | SEC FORM 4 Code M | —8,073 | filing |
| 8 Jul 2026filed 9 Jul 2026 | QTRX Quanterixoption or derivative · Life-science tools | SEC FORM 4 Code M | —8,073 at $0.00 | filing |
| 8 Jul 2026filed 9 Jul 2026 | QTRX Quanterixoption or derivative · Life-science tools | SEC FORM 4 Code M | —8,073 at $0.00 | filing |
| 8 Jul 2026filed 9 Jul 2026 | QTRX QuanterixLife-science tools | SEC FORM 4 Code M | —8,073 | filing |
| 4 May 2026filed 6 May 2026 | WST West Pharmaceutical ServicesMedical Devices | SEC FORM 4 Code A | —791 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | WST West Pharmaceutical ServicesMedical Devices | SEC FORM 4 Code A | —791 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | QTRX QuanterixLife-science tools | SEC FORM 4 Code A | —23,372 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | QTRX QuanterixLife-science tools | SEC FORM 4 Code A | —1,944 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | QTRX QuanterixLife-science tools | SEC FORM 4 Code A | —23,372 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | QTRX QuanterixLife-science tools | SEC FORM 4 Code A | —1,944 at $0.00 | filing |
| 1 Oct 2025filed 3 Oct 2025 | QTRX QuanterixLife-science tools | SEC FORM 4 Code A | $12K2,084 at $5.54 | filing |
| 8 Jul 2025filed 10 Jul 2025 | Akoya Biosciencesoption or derivative | SEC FORM 4 Code J | —38,993 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | Akoya Biosciencesoption or derivative | SEC FORM 4 Code J | —30,549 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | Akoya Biosciencesoption or derivative | SEC FORM 4 Code J | —56,322 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | Akoya Biosciencesoption or derivative | SEC FORM 4 Code J | —50,000 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | Akoya Biosciences | SEC FORM 4 Code J | —20,000 | filing |
| 8 Jul 2025filed 10 Jul 2025 | QTRX Quanterixoption or derivative · Life-science tools | SEC FORM 4 Code A | —50,758 at $0.00 | filing |
| 8 Jul 2025filed 10 Jul 2025 | QTRX QuanterixLife-science tools | SEC FORM 4 Code A | —2,940 | filing |
| 8 Jul 2025filed 10 Jul 2025 | QTRX QuanterixLife-science tools | SEC FORM 4 Code A | —24,464 at $0.00 | filing |
| 6 May 2025filed 8 May 2025 | WST West Pharmaceutical ServicesMedical Devices | SEC FORM 4 Code A | —1,071 at $0.00 | filing |
News
Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 MlnLH · finanzen.ch · 20 Oct 2026Labcorp To Acquire BioReference Health Assets; OPKO Shares Rise 7.35%LH · rttnews.com · 15 Oct 2026Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference HealthLH · prnewswire.com · 15 Oct 2026
0 headlines in the last 90 days name Goldman Myla Lai; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.